Desmopressin
Desmopressin is a peptide, indexed here under Endocrine and immune signalling peptides.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Endocrine and immune signalling peptides |
| CAS registry number | 16679-58-6[1] |
| PubChem CID | 5311065[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C46H64N14O12S2[1] |
| Molecular weight | 1069.2 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Desmopressin, reported in the literature as DDAVP, is a synthetic analogue of vasopressin. The Drugs@FDA register returned approved applications under this generic name; those products are recorded in the regulatory status field and are not what this page describes. A 1985 Annals of Internal Medicine review carries the name as its title, and a 2003 Journal of Thrombosis and Haemostasis paper reports the cellular mechanisms of its haemostatic effects.
The retrieved clinical records are haematological: a 1986 New England Journal of Medicine double-blind randomised trial on blood loss after cardiac surgery, 1988 and 1997 Blood reviews on its use in congenital and acquired bleeding disorders, 2004 and 2008 Blood papers on the biological response in type 1 and type 2 von Willebrand disease and its dependence on genotype and phenotype, and a 1992 British Journal of Haematology paper on tachyphylaxis after repeated doses in haemophilia and von Willebrand disease. A 2002 BJU International paper reports a double-blind placebo-controlled study in nocturia in men, and a 2004 Journal of Controlled Release paper reports transdermal delivery through a coated microneedle array.
[3, 4, 5, 6, 7, 8, 9, 10, 11, 12]Reported mechanism
A synthetic vasopressin analogue selective for the V2 receptor; the retrieved records report antidiuretic and haemostatic effects, the latter through release of von Willebrand factor.
[4, 3]Stated in the titles of the cited 2003 Journal of Thrombosis and Haemostasis and 1985 Annals of Internal Medicine papers.
Targets named in the cited records: vasopressin V2 receptor, von Willebrand factor release.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 20 application record(s) for this compound name (including ANDA091280, NDA219873, ANDA210218, ANDA210223, ANDA219981, marketed as DESMOPRESSIN ACETATE, DESMODA). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Desmopressin appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- DDAVP
- desmopressin acetate
- 1-deamino-8-D-arginine vasopressin
Where this page sits
Research records
Cited research records for Desmopressin, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Vasopressin — Endocrine and immune signalling peptides
- Oxytocin — Endocrine and immune signalling peptides
Class page: Endocrine and immune signalling peptides. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Desmopressin?
Desmopressin, reported in the literature as DDAVP, is a synthetic analogue of vasopressin. The Drugs@FDA register returned approved applications under this generic name; those products are recorded in the regulatory status field and are not what this page describes.
Which class is Desmopressin indexed under?
Desmopressin is indexed under Endocrine and immune signalling peptides. This class groups peptides whose retrieved literature concerns endocrine or immune signalling outside the growth hormone axis.
What does the FDA application register show for Desmopressin?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 20 application record(s) for this compound name (including ANDA091280, NDA219873, ANDA210218, ANDA210223, ANDA219981, marketed as DESMOPRESSIN ACETATE, DESMODA). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.
Sources
- PubChem Compound Summary for CID 5311065, Desmopressin. PubChem, National Library of Medicine (2026). pubchem:5311065
- Drugs@FDA application register query for this compound, 20 application(s) returned: ANDA091280, NDA219873, ANDA210218, ANDA210223, ANDA219981. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:desmopressin
- Desmopressin. Annals of internal medicine (1985). pmid:3893256
- Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). Journal of thrombosis and haemostasis : JTH (2003). pmid:12871401
- Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. The New England journal of medicine (1986). pmid:3517650
- Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood (1988). pmid:3052622
- Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood (1997). pmid:9326215
- Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood (2004). pmid:14630825
- Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood (2008). pmid:18230755
- Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). British journal of haematology (1992). pmid:1419807
- Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU international (2002). pmid:12010228
- Transdermal delivery of desmopressin using a coated microneedle array patch system. Journal of controlled release : official journal of the Controlled Release Society (2004). pmid:15212882
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.